Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.63 USD
+0.38 (2.67%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $14.64 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Stoke Therapeutics, Inc. (STOK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.14 | $35.00 | $14.00 | 55.37% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Stoke Therapeutics, Inc. comes to $22.14. The forecasts range from a low of $14.00 to a high of $35.00. The average price target represents an increase of 55.37% from the last closing price of $14.25.
Analyst Price Targets (7 )
Broker Rating
Stoke Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/STOK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Rudy Li | Strong Buy | Strong Buy |
7/11/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
6/28/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/26/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $22.14 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 70 of 253 |
Current Quarter EPS Est: | -0.55 |